CompletedPhase 1/2

A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

United States75 participantsStarted 2014-04

Plain-language summary

The goal of this study is to investigate whether using bevacizumab (Avastin®) is both safe and effective at decreasing the likelihood of a high-risk corneal graft rejection. Patients who are "high-risk" for rejection have blood vessels growing from the white of the eye into the cornea (clear, front region of the eye). The medication is used at the time of surgery and in the weeks following surgery. Participants have a 50/50 chance at receiving the active study medication or a placebo medication.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Presence of corneal NV in one or more quadrants (≥ 3 clock hours NV ≥ 2mm from the limbus) OR
✓. Extension of corneal NV to graft-host junction in a previous failed graft

What they're measuring

Endothelial Rejection Rate

Timeframe: 12 Months

Number of Participants Experiencing Ocular Adverse Events

Timeframe: 12 months

Incidence of Systemic Adverse Events

Timeframe: 12 Months

Trial details

NCT IDNCT01996826

SponsorReza Dana, MD

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-04

Results submitted2020-05-04

View on ClinicalTrials.gov More Corneal Neovascularization trials